1. Home
  2. MIRM vs PATH Comparison

MIRM vs PATH Comparison

Compare MIRM & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

SELL

Current Price

$92.00

Market Cap

7.2B

Sector

Health Care

ML Signal

SELL

Logo UiPath Inc.

PATH

UiPath Inc.

SELL

Current Price

$12.39

Market Cap

7.3B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
MIRM
PATH
Founded
2018
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
7.3B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MIRM
PATH
Price
$92.00
$12.39
Analyst Decision
Strong Buy
Hold
Analyst Count
12
20
Target Price
★ $157.71
$15.41
AVG Volume (30 Days)
548.2K
★ 22.4M
Earning Date
11-03-2026
12-03-2026
Dividend Yield
N/A
N/A
EPS Growth
74.59
★ 500.00
EPS
N/A
★ 0.11
Revenue
$19,138,000.00
★ $1,610,572,000.00
Revenue This Year
$37.65
$11.28
Revenue Next Year
$21.04
$8.25
P/E Ratio
★ N/A
$119.55
Revenue Growth
N/A
★ 12.65
52 Week Low
$63.23
$9.20
52 Week High
$130.00
$19.84

Technical Indicators

Market Signals
Indicator
MIRM
PATH
Relative Strength Index (RSI) 52.45 39.17
Support Level $87.38 $10.58
Resistance Level $98.34 $13.33
Average True Range (ATR) 4.20 0.49
MACD 0.35 -0.05
Stochastic Oscillator 48.74 8.92

Price Performance

Historical Comparison
MIRM
PATH

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

About PATH UiPath Inc.

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies, including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries, including claims processing, employee onboarding, invoice-to-cash, loan applications, and customer service. The company works in the Americas, Europe, the Middle East, and Africa, and Asia-Pacific, with the maximum revenue from the America.

Share on Social Networks: